AGN:CSE; AGNPF:OTCQB; AGN0:XFRA

Algernon Pharmaceuticals Inc.

Algernon is a clinical stage drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
Algernon has filed new intellectual property rights globally for its lead drug NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.
AGN:CSE AGNPF:OTCQB AGN0:XFRA

Expert Comments:

read more >
read more >
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough — only to learn that it treated chronic cough far better than first thought.
read more >

Clive Maund, CliveMaund.com

(7/28/22)
"Algernon Pharmaceuticals Inc. came out with very good news this morning that the data from its Phase 2 study of ifenprodil is much better than expected. This is thought likely to get the stock moving again, and so we are considered to be at another good buy spot here."

headshot of André Uddin

André Uddin, Research Capital Corporation

(7/28/22)
"After conducting additional statistical review of the Phase 2a data in idiopathic pulmonary fibrosis (IPF) patients with chronic cough, key opinion leader Dr. Jacky Smith noted that Algernon Pharmaceuticals Inc.'s cough data showed a significant improvement in mean objective 24-hour and waking cough counts after four and 12 weeks. . .it is our belief that it would be logical to develop ifenprodil for two indications: in IPF patients and also in IPF patients who have chronic cough."

Vancouver-based pharmaceutical development firm Algernon Pharmaceuticals Inc. recently reported topline data from a Phase 2a trial of ifenprodil in IPF patients with chronic cough that met its endpoint and demonstrated promising initial efficacy. Research Capital Corp. advised that it is maintaining its CA$25.00/share price target and "Speculative Buy" rating on the company.
read more >

André Uddin, Research Capital Corporation

(7/18/22)
"Algernon Pharmaceuticals Inc. reported topline results of a Phase 2a trial with ifenprodil in idiopathic pulmonary fibrosis (IPF) patients with chronic cough. The IPF data hit its endpoint, showing promising initial efficacy. . .we recommend investors with a higher risk tolerance to aggressively purchase the stock."

read more >

Clive Maund, CliveMaund.com

(6/1/22)
"Algernon Pharmaceuticals Inc. is at a very good price and looks like it is shaping up for a breakout into a new bull market. This is a stock that is made much more attractive by the fact that it only has about 1.6M shares in issue as a result of a recent 1 for 100 share rollback. . .the stock is only at about 6% of the price at its 2016 peak."

read more >
read more >

Clive Maund, CliveMaund.com

(2/2/22)
"We can see entry and exit points on the latest three-month chart of Algernon Pharmaceuticals Inc. stock and how it has reacted back in a satisfactory manner to another good buy spot, with the technical setup now very positive. The time has thus arrived to buy back the position we sold at a much higher price; it is rated a Strong buy again here, especially as the broad stock market is on the up again."

headshot of André Uddin

André Uddin, Research Capital Corporation

(1/28/22)
"For Algernon Pharmaceuticals Inc., the results of the ongoing Phase 2a trial in idiopathic pulmonary fibrosis/chronic cough (Q2/22) represent an important near-term catalyst investors should watch. . .we believe the company is back on track and focused on developing its pipeline. We consider Algernon's current valuation favorable from a risk-reward standpoint."

More Expert Comments

Experts Following This Company

Clive Maund – CliveMaund.com
headshot of Bob Moriarty
Bob Moriarty, Author – 321 Gold
headshot of Penny Queen
Penny Queen, Mother, Investor and Social Media Leader
headshot of André Uddin
André Uddin – Research Capital Corporation

Company News 

8/3/2022 – Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

7/28/2022 – Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

7/18/2022 – Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

7/11/2022 – Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

7/7/2022 – Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

7/5/2022 – Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

7/4/2022 – Algernon Pharmaceuticals Announces Closing of Public Offering of Units

6/27/2022 – Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

6/22/2022 – Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

6/21/2022 – Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

6/15/2022 – Algernon Pharmaceuticals Announces Public Offering of Units

6/13/2022 – Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.See disclaimer for more details.

Investing Highlights
 
Advancing new drug treatments for billion dollar global disease markets.
 
Conducting multiple phase II clinical trials
 
Experienced management team & globally recognized medical advisory board
catalyst Calendar
Q2
2021
U,S, FDA End-of-Phase 2 COVID-19 Study Meeting, Q2, 2021
Q4
2021
Phase 2 trial for IPF and chronic cough data expected Q4, 2021.
Q4
2021
Phase 1 Study planned for DMT, Q4 2021